NetworkNewsBreaks – Willow Biosciences Inc. (TSX
Post# of 23
(Total Views: 109)
Posted On: 10/08/2020 3:14:09 PM
NetworkNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) to Support Research on Therapeutic Potential of Non-Psychoactive Cannabinoids
Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a Vancouver, Canada-based company focused on manufacturing pharmaceutical-grade cannabinoids via synthetic biology, today announced its partnership with researchers at the University of Lethbridge and the University of Calgary. According to the update, the collaboration is designed to study the therapeutic potential of non-psychoactive cannabinoids in relation to intestinal inflammation, abdominal pain and depression. Alberta Innovates financially supports these studies that involve laboratory testing in preclinical models of disease. Willow will be providing four different, non-plant derived cannabinoids for use in the study, which is set to begin in the fourth quarter of 2020. “Willow is excited to be supporting research on the effects of cannabinoids that could ultimately have an impact on human health,” Willow’s CEO Trevor Peters said in the news release. “Dr. Gruber and his team of Alberta researchers are world renowned for their expertise in neuroscience, pain and the interplay between the gut, brain and endocannabinoid system, that is the target of action of non-psychoactive cannabinoids in the human body.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a Vancouver, Canada-based company focused on manufacturing pharmaceutical-grade cannabinoids via synthetic biology, today announced its partnership with researchers at the University of Lethbridge and the University of Calgary. According to the update, the collaboration is designed to study the therapeutic potential of non-psychoactive cannabinoids in relation to intestinal inflammation, abdominal pain and depression. Alberta Innovates financially supports these studies that involve laboratory testing in preclinical models of disease. Willow will be providing four different, non-plant derived cannabinoids for use in the study, which is set to begin in the fourth quarter of 2020. “Willow is excited to be supporting research on the effects of cannabinoids that could ultimately have an impact on human health,” Willow’s CEO Trevor Peters said in the news release. “Dr. Gruber and his team of Alberta researchers are world renowned for their expertise in neuroscience, pain and the interplay between the gut, brain and endocannabinoid system, that is the target of action of non-psychoactive cannabinoids in the human body.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Willow Biosciences Inc. (CANSF) Stock Research Links
Scroll down for more posts ▼